Viemed Q3 2026 Earnings: Revenue Rises 12.2% as Profitability Rebounds

Viemed Healthcare (NASDAQ: VMD) reported Q3 2026 net revenue of $80.7 million, up 12.2% year over year, while diluted EPS increased to $0.11 from $0.09. Net income attributable to Viemed rose 32.0% to $4.6 million, and adjusted EBITDA margin recovered sharply from the preceding quarter despite remaining below its prior-year level. The company also raised the lower end of its full-year revenue guidance and reduced its capital expenditure outlook.

Core Financial Results

Gross profit increased 11.7% to $46.2 million, broadly matching revenue growth and leaving gross margin nearly unchanged. Operating income grew faster, rising approximately 23.4% as selling, general and administrative expenses increased at a slightly slower rate than revenue. Lower net interest expense, which fell to $177,000 from $507,000, also supported the 32.0% increase in attributable net income.

Adjusted EBITDA growth was more moderate at 5.8%, resulting in a year-over-year margin decline. All dollar figures in the table are in U.S. dollars.

Adjusted EBITDA and free cash flow are non-GAAP measures. Viemed defines free cash flow as operating cash flow less net capital expenditures.

Business and Operating Trends

Ventilator rental revenue increased 7.4% to $37.5 million, supported by higher average patient volumes. The company ended the quarter with 12,552 ventilator patients. Ventilator rental represented approximately 46% of total quarterly revenue, while its growth rate remained below the company-wide increase.

Patient growth was faster in Viemed’s sleep-related operations. PAP therapy patients increased 37.5% year over year and 16.0% sequentially to 43,861, while sleep resupply patients rose 22.1% year over year and 10.5% sequentially to 40,918. The company did not disclose corresponding revenue figures for these patient categories, so their precise contribution to consolidated growth cannot be determined.

Q3 was Viemed’s first full year-over-year quarterly comparison following the Lehan acquisition. That means the 12.2% consolidated revenue increase was measured against a prior-year base that already included the acquired business for a full quarter, rather than benefiting from a partial-period acquisition comparison.

Sequential Profitability Recovered Faster Than Revenue

The most significant change during the quarter was the sequential rebound in profitability. Revenue grew 3.3% from Q2, while adjusted EBITDA increased 24.4% and attributable net income rose 67.8%. Adjusted EBITDA margin improved to 21.1% from 17.6%, and attributable net income margin increased to 5.7% from 3.5%.

Management attributed the improvement to progress following investments made earlier in 2026 and said further efficiency opportunities remain as those initiatives mature. However, adjusted EBITDA margin was still approximately 130 basis points below Q3 2025, making the improvement primarily a sequential recovery rather than year-over-year margin expansion.

The company’s lower capital expenditure outlook adds another dimension to the profitability change. Management expects less capital-intensive products and services to account for a greater share of revenue, which supported the reduction in projected net capital expenditures.

Cash Flow and Balance Sheet

Viemed generated $11.5 million of operating cash flow during the quarter. After $7.5 million of net capital expenditures, free cash flow was $4.0 million. For the trailing 12 months, operating cash flow totaled $53.9 million and free cash flow reached $26.1 million.

For the first nine months of 2026, operating cash flow increased to $35.5 million from $33.5 million. Working capital absorbed part of that cash generation: accounts receivable used $9.3 million of cash, while prepaid expenses and other assets used another $6.0 million. Accounts receivable ended the quarter at $34.9 million, up from $25.6 million at the end of 2025.

The company finished Q3 with $9.7 million in cash, $12.0 million in working capital, and approximately $46 million available under existing credit facilities. Total debt was approximately $5.0 million, down from $12.4 million at the end of 2025. During the quarter, Viemed repaid $2.1 million of term debt and repurchased 115,000 shares for approximately $1.0 million, excluding taxes.

2026 Guidance

Viemed raised the lower end of its revenue outlook, narrowed the adjusted EBITDA range, and lowered expected net capital expenditures. The revisions indicate greater revenue visibility and lower expected capital intensity, although the reduced upper end of the EBITDA range also limits the previous upside range.

Management expects sequential improvement in both revenue and adjusted EBITDA during Q4. The guidance excludes potential acquisitions and other strategic transactions, and Viemed does not provide a GAAP reconciliation for adjusted EBITDA guidance because certain adjustments cannot be reliably forecast.

Recent Insider Transactions

Separate six-month aggregate data showed 87,312 shares purchased across five insider transactions and 30,000 shares sold across two transactions, resulting in net purchases of 57,312 shares. Detailed terms for the purchase transactions were not available in the supplied data.

The following recent sales had a clear date, seller, transaction direction, and reported value. These transactions alone do not establish insiders’ views about the company’s prospects.

Risks Investors Should Monitor

• Adjusted EBITDA margin remains below last year: The sequential recovery was substantial, but the Q3 margin was still approximately 130 basis points below the prior-year quarter. Sustaining the operating leverage described by management remains important.
• Working capital is consuming cash: Higher accounts receivable and prepaid assets absorbed a combined $15.3 million of cash during the first nine months of 2026, limiting the conversion of earnings into cash.
• The business remains capital intensive: Q3 operating cash flow of $11.5 million translated into only $4.0 million of free cash flow after net capital expenditures. Even after the guidance reduction, net capital expenditures are expected to equal 8.0% to 9.0% of full-year revenue.
• Reimbursement and payor exposure: Changes in reimbursement rates, claims audits, and dependence on a limited number of payors could affect revenue, margins, and cash collection.
• Execution across a broader platform: Viemed is relying on growth across respiratory, sleep, and women’s health offerings. Continued expansion requires the company to manage patient growth, operating efficiency, and integration across its diversified operations.

Summary

Viemed’s Q3 2026 results combined double-digit revenue growth with faster growth in GAAP operating income and net income. Profitability improved substantially from Q2 as earlier investments began producing operating leverage, although adjusted EBITDA margin remained below the prior-year level. The key items to monitor are whether the sequential margin recovery continues, whether faster-growing sleep-related operations translate into stronger revenue contributions, and whether the shift toward less capital-intensive offerings improves free cash flow conversion.